Sandoz has filed what it calls a “defensive” lawsuit against the US Centers for Medicare and Medicaid Services related to the ongoing possibility that two of its drugs could be classified as ‘innovator’ drugs under the Medicaid drug rebate program statute and subject to higher rebates.
Six years ago, CMS told Sandoz that two of its drugs should be classified as innovator drugs: Anectine (succinylcholine chloride),...